



Stablepharma™

Stable Vaccines - Eliminating Waste

Stablepharma Patent Pack

StablevaX™ has had patents granted
in 14 international jurisdictions

August 2020


stablepharma.com

Stablepharma Limited - Improved Injections Patent Family

Country	Mewburn Ref; Client Ref	Status	Application Number	Patent Number
EP (Germany)	2753424; Improved Injections EP	Granted	13703463.3	602013008576.5
EP (France)	2753432; Improved Injections EP	Granted	13703463.3	2806854
EP (UK)	2753440; Improved Injections EP	Granted	13703463.3	2806854
EP (Italy)	2753457; Improved Injections EP	Granted	13703463.3	502016000092151
EP (Netherlands)	2753465; Improved Injections EP	Granted	13703463.3	2806854
United States of America	6993547; Improved Injections US	Pending	14/372146	
Brazil	6993554; Improved Injections BR	Granted	GB2013050183	BR112014018576-0
China	6993562; Improved Injections CN	Granted	201380016161.3	ZL201380016161.3
Japan	6993570; Improved Injections JP	Granted	2014-553808	5976843
India	6993588; Improved Injections IN	Granted	1411/MUMNP/2014	299079
Mexico	6993596; Improved Injections MX	Granted	MX/A/2014/009081	350159
Australia	6993612; Improved Injections AU	Granted	2013213448	2013213448
South Africa	6993620; Improved Injections ZA	Granted	2014/06703	2014/06703
Africa (ARIPO)	6993638; Improved Injections AP	Granted	AP/P/2014/007896	AP3655
Canada	6993646; Improved Injections CA	Granted	2896377	2896377



AFRICA



Australian Government
IP Australia

CERTIFICATE OF GRANT STANDARD PATENT

2013213448

The Commissioner of Patents has granted the above patent on 18 May 2017, and certifies that the following are the particulars of this patent appearing in the Register of Patents:

Name and Address of Patentee(s):
Stablepharma Ltd
Lennox House, 3 Pierrepont Street, Bath, BA1 1LB, United Kingdom.


Name of Actual Inventor(s):
Roser, Bruce

Title of Invention:
Improved injections

Term of Patent:
Twenty years from 28 January 2013

Priority Details

<i>Number</i>	<i>Date</i>	<i>Filed with</i>
1201426.2	27 January 2012	GB



Dated this 18th day of May 2017
Commissioner of Patents

PATENTS ACT 1990
The Australian Patents Register is the official record and should be referred to for the full details pertaining to this IP Right.

AUSTRALIA



SERVIÇO PÚBLICO FEDERAL
MINISTÉRIO DA ECONOMIA
INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL
PRESIDÊNCIA

COORDENAÇÃO-GERAL DE RECURSOS E PROCESSOS ADMINISTRATIVOS DE NULIDADE

N.º do Pedido: BR112014018576-0 **N.º de Depósito PCT:** GB2013050183
Data de Depósito: 28/01/2013
Prioridade Unionista: GB 1201426.2 (27/01/2012)
Depositante: STABLEPHARMA LTD (GB)
Inventor: BRUCE ROSER
Título: "INSERTO DE MATRIZ POROSA COMPRESSÍVEL, MÉTODO PARA PRODUZIR O MESMO, CONJUNTO DE PEÇAS, SERINGA FARMACÉUTICA E MÉTODO PARA PRÉ-CARREGAR UMA SERINGA"

SUBSÍDIOS TÉCNICOS

Senhor Presidente,

O parecer colegiado da COREP/CGREC considerou que as alegações do recurso são procedentes. O pedido atende às necessárias condições de patenteabilidade, sendo sugerida a reforma da decisão de indeferimento, com o conseqüente deferimento do pedido na forma estipulada no dito parecer.

Recurso conhecido e provido. Reformada a decisão recorrida e deferido o pedido [código 100].

Rio de Janeiro, 22 de maio de 2020.

Heleno José Costa Bezerra Netto
Pesquisador / Mat. Nº 1530931
Portaria INPI/PR Nº 24 de 11/01/2019
CGREC / COREP

Leila Freire Falcone
Coordenadora/ Mat. Nº 0449354
Portaria MDIC nº 299 de 20/10/2016
CGREC/COREP



Innovation, Sciences et
Développement économique Canada
Office de la propriété intellectuelle du Canada

Innovation, Science and
Economic Development Canada
Canadian Intellectual Property Office

Brevet canadien / Canadian Patent

Le commissaire aux brevets a reçu une demande de délivrance de brevet visant une invention. Ladite requête satisfait aux exigences de la Loi sur les brevets. Le titre et la description de l'invention figurent dans le mémoire descriptif, dont une copie fait partie intégrante du présent document.

Le présent brevet confère à son titulaire et à ses représentants légaux, pour une période expirant vingt ans à compter de la date du dépôt de la demande au Canada, le droit, la faculté et le privilège exclusif de fabriquer, construire, exploiter et vendre à d'autres, pour qu'ils l'exploitent, l'objet de l'invention, sauf jugement en l'espèce rendu par un tribunal compétent, et sous réserve du paiement des taxes périodiques.



The Commissioner of Patents has received a petition for the grant of a patent for an invention. The requirements of the Patent Act have been complied with. The title and a description of the invention are contained in the specification, a copy of which forms an integral part of this document.

The present patent grants to its owner and to the legal representatives of its owner, for a term which expires twenty years from the filing date of the application in Canada, the exclusive right, privilege and liberty of making, constructing and using the invention and selling it to others to be used, subject to adjudication before any court of competent jurisdiction, and subject to the payment of maintenance fees.

BREVET CANADIEN	2,896,377	CANADIAN PATENT
Date à laquelle le brevet a été accordé et délivré	2019/01/08	Date on which the patent was granted and issued
Date du dépôt de la demande	2013/01/28	Filing date of the application
Date à laquelle la demande est devenue accessible au public pour consultation	2013/08/01	Date on which the application was made available for public inspection

Commissaire aux brevets / Commissioner of Patents






(CIPO-91)
04-12-17



CHINA

	Europäisches Patentamt European Patent Office Office européen des brevets		
URKUNDE	CERTIFICATE	CERTIFICAT	
Es wird hiermit bescheinigt, dass für die in der Patentschrift beschriebene Erfindung ein europäisches Patent für die in der Patentschrift bezeichneten Vertragsstaaten erteilt worden ist.	It is hereby certified that a European patent has been granted in respect of the invention described in the patent specification for the Contracting States designated in the specification.	Il est certifié qu'un brevet européen a été délivré pour l'invention décrite dans le fascicule de brevet, pour les Etats contractants désignés dans le fascicule de brevet.	
Europäisches Patent Nr.	European patent No.	Brevet européen n°	
	2806854		
Patentinhaber	Proprietor of the patent	Titulaire du brevet	
Stablepharma Ltd 3 Northumberland Buildings Bath, Somerset BA1 2JB/GB			
FM/EP/0024/2021/0720	München, den Munich, Fait à Munich, le.	15.06.16	
			Benoit Battistelli Präsident des Europäischen Patentamts President of the European Patent Office Président de l'Office européen des brevets




EUROPE

 <p>INTELLECTUAL PROPERTY INDIA PATENTS DESIGNS TRADE MARKS GEOGRAPHICAL INDICATIONS</p>	 <p>सत्यमेव जयते भारत सरकार GOVERNMENT OF INDIA पेटेंट कार्यालय THE PATENT OFFICE पेटेंट प्रमाणपत्र PATENT CERTIFICATE (Rule 74 Of The Patents Rules)</p>	क्रमांक : 022102707 SL No :	
पेटेंट सं. / Patent No.	:	299079	
अवेदन सं. / Application No.	:	1411/MUMNP/2014	
फाइल करने की तारीख / Date of Filing	:	28/01/2013	
पेटेटी / Patentee	:	STABLEPHARMA LTD,	
<p>प्रमाणित किया जाता है कि पेटेटी को उपरोक्त आवेदन में यथाप्रकटित IMPROVED INJECTIONS नामक आविष्कार के लिए, पेटेंट अधिनियम, 1970 के उपबंधों के अनुसार आज तारीख 28th day of January 2013 से बीस वर्ष की अवधि के लिए पेटेंट अनुदान किया गया है।</p> <p>It is hereby certified that a patent has been granted to the patentee for an invention entitled IMPROVED INJECTIONS as disclosed in the above mentioned application for the term of 20 years from the 28th day of January 2013 in accordance with the provisions of the Patents Act,1970.</p>			
<p>INTELLECTUAL PROPERTY INDIA PATENTS DESIGNS TRADE MARKS GEOGRAPHICAL INDICATION</p>			
			
अनुदान की तारीख : 23/07/2018 Date of Grant :		पेटेंट नियंत्रक Controller of Patent	
<p>टिप्पणी - इस पेटेंट के नवीकरण के लिए फीस यदि इसे बनाए रखा जाना है, 28th day of January 2015 से और उसके पश्चात प्रत्येक वर्ष में इसी दिन देव होगी। Note: - The fees for renewal of this patent, if it is to be maintained will fall / has fallen due on 28th day of January 2015 and on the same day in every year thereafter.</p>			



JAPAN



TÍTULO DE PATENTE No. 350159

Titular(es):	STABLEPHARMA LIMITED		
Domicilio:	Lennox House, 3 Pierrepont Street, Bath, BA1 1LB, INGLATERRA		
Denominación:	INYECCIONES MEJORADAS.		
Clasificación:	CIP:	A61K9/00; A61M5/178	
	GPC:	A61K9/0019; A61K9/122; A61L31/16; A61L31/026; A61L31/125; A61L31/146; A61M5/178; A61M5/3129; A61L2300/438; A61M5/3145	
Inventor(es):	BRUCE ROSER		

<p>Número: MX/a/2014/009081</p> <p>País: GB</p>	<p>Fecha de Presentación Internacional: 28 de Enero de 2013</p> <p>PRIORIDAD</p> <p>Fecha: 27 de enero de 2012</p> <p>Número: 1201426.2</p>
-----------------------------------------------------------------------	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Vigencia: Veinte años
Fecha de Vencimiento: 28 de enero de 2033
Fecha de Expedición: 29 de agosto de 2017


La patente de referencia se otorga con fundamento en los artículos 1°, 2° fracción V, 6° fracción III, y 56 de la Ley de la Propiedad Industrial.

De conformidad con el artículo 23 de la Ley de la Propiedad Industrial, la presente patente tiene una vigencia de veinte años prorrogables, contada a partir de la fecha de presentación de la solicitud internacional y estará sujeta al pago de la tarifa para mantener vigentes los derechos.

Quien suscribe el presente título lo hace con fundamento en lo dispuesto por los artículos 6° fracciones III y 2° bis 2 de la Ley de la Propiedad Industrial (Diario Oficial de la Federación (D.O.F.) 27/05/1991, reformado el 02/08/1994, 25/10/1996, 26/12/1997, 17/05/1998, 25/01/2004, 16/08/2009, 25/01/2008, 06/05/2008, 06/01/2010, 18/06/2010, 26/06/2010, 27/01/2012 y 05/04/2012), artículos 1°, 3° fracción V inciso a), 4° y 12° fracciones I y III del Reglamento del Instituto Mexicano de la Propiedad Industrial (D.O.F. 14/12/1998, reformado el 01/02/2002, 15/07/2004, 28/07/2004 y 7/09/2007), artículos 1°, 3°, 4°, 5° fracción V inciso a), 18° fracciones I y III, y 30 del Estatuto Orgánico del Instituto Mexicano de la Propiedad Industrial (D.O.F. 27/12/1998, reformado el 10/10/2002, 29/07/2004, 04/08/2004 y 13/09/2007), 1° 3° y 5° inciso a) del Acuerdo que delega facultades en los Directores Generales Adjuntos, Coordinador, Directores Divisionales, Titulares de las Oficinas Regionales, Subdirectores Divisionales, Coordinadores Departamentales y otros subalternos del Instituto Mexicano de la Propiedad Industrial (D.O.F. 15/12/1999, reformado el 04/02/2000, 25/07/2004, 04/08/2004 y 13/09/2007).

El presente oficio se signa con firma electrónica avanzada (FIEL), con fundamento en los artículos 7 BIS 2 de la Ley de la Propiedad Industrial, 3o de su Reglamento, y 1 fracción III, 2 fracción V, 26 BIS y 28 TER del Acuerdo por el que se establecen los lineamientos para el uso del Portal de Pagos y Servicios Electrónicos (PASE) del Instituto Mexicano de la Propiedad Industrial, en los trámites que se indican.


LA DIRECTORA DIVISIONAL DE PATENTES
NAHANNY CANAL REYES



Cadena Original:
NAHANNY MARISOL CANAL REYES|0000100000403252792|Servicio de Administración Tributaria|1696|MX|2017/11197|MX/a/2014/009081|Título de patente PCT|1027|RGZ|Pág(6)
1|yG2HUdJhRQ8Ex9i5FKY125mst8=

Sello Digital:
VR3EjZAR0TGx0C+HREZhrDw8BkRrXc5+nbHcITMa+SnyP7ahV5yPQIEgDahY3iAYU0AK9Ra55111wCM97Du
15ZCfygEghoNA7IhmTEMS8yLz5Ym0PuN9L9ocJhTKLj9d1iunKdvw4Yr9OOqghG6Z+K90nqQE31zALJEBxz
RwR9isEF8wCF8kRHoFJazadJzDvXVCW56FZ03UjhbJmxfWu1v1PKP8q4kCleW6U5YE4EnUjKbomVHHd3hc
ch4Q2x449gRQsZdotMqb3covQcKvRna57B8gpc6dS9gQkVMSQHPraDxGVG26EFvyQDw==

Arenal No. 550, Piso 1, Pueblo Santa María Tzepepan, Xochimilco, 16020,
Ciudad de México.
(55)53340700 www.gob.mx/impi


 MX/2017/1197



SOUTH AFRICA

MewburnEllis
LLP

INTERNATIONAL (PCT) PATENT APPLICATIONS

PCT Member States (146) - as at 1 July 2012

An "international" or "PCT" patent application covers all countries/regions which are party to the Patent Cooperation Treaty (PCT) ("PCT Member States") on the day the PCT application is filed, except those which the applicant has deliberately excluded or withdrawn. At present, the PCT covers most of the major industrial countries of the world, including not only Europe, Pakistan, Australia, Venezuela and most of the Arab world. This sheet provides a complete list of the PCT Member States. For more information about PCT applications and the PCT process, see our information sheet entitled PCT Applications.

Albania - AL ¹	Ecuador - EC	Liberia - LR	St Kitts and Nevis - KN
Algeria - DZ	El Salvador - SV	Liechtenstein - LI (EP)	St Lucia - LC
Angola - AO	Egypt - EG	Lithuania - LT (EP)	St Vincent & Grenadines - VC
Antigua and Barbuda - AG	Equatorial Guinea - GQ (OA) ²	Luxembourg - LU (EP)	San Marino - SM (EP)
Armenia - AM (EA)	Estonia - EE (EP)	Libyan Arab Jamahiriya - LY	Sao Tome and Principe - ST
Australia - AU			Senegal - SN (OA) ²
Austria - AT (EP)	Finland - FI (EP)	Macdonia - MK	Serbia - RS ⁴
Azerbaijan - AZ (EA)	France - FR (EP) ²	Madagascar - MG	Seychelles - SC
		Malawi - MW (AP)	Sierra Leone - SL (AP)
Bahrain - BH	Gabon - GA (OA) ²	Malaysia - MY	Singapore - SG ✓
Barbados - BB	Gambia - GM (AP)	Mali - ML (OA) ²	Slovakia - SK (EP)
Belarus - BY (EA)	Georgia - GE	Malta - MT (EP) ²	Slovenia - SI (EP) ²
Belgium - BE (EP) ²	Germany - DE (EP)	Mauritania - MR (OA) ²	South Africa - ZA
Belize - BZ	Ghana - GH (AP)	Mexico - MX	Spain - ES (EP)
Benin - BJ (OA) ²	Greece - GR (EP) ²	Moldova - MD ²	Sri Lanka - LK
Bosnia & Herzegovina - BA ¹	Grenada - GD	Monaco - MC (EP) ²	Sudan - SD (AP)
Botswana - BW (AP)	Guatemala - GT	Mongolia - MN	Swaziland - SZ (AP) ²
Brazil - BR	Guinea - GN (OA) ²	Montenegro - ME ^{1,4}	Sweden - SE (EP)
Brunei Darussalam - BN ⁴	Guinea-Bissau - GW (OA) ²	Morocco - MA	Switzerland - CH (EP)
Bulgaria - BG (EP)		Mozambique - MZ (AP)	Syrian Arab Republic - SY
Burkina Faso - BF (OA) ²	Honduras - HN		
	Hungary - HU (EP)	Namibia - NA	Tajikistan - TJ (EA)
Cameroon - CM (OA) ²	Iceland - IS (EP)	Netherlands - NL (EP) ²	Tanzania - TZ (AP)
Canada - CA	India - IN ✓	New Zealand - NZ	Thailand - TH
Central African Rep. - CF (OA) ²	Indonesia - ID	Nicaragua - NI	Togo - TG (OA) ²
Chad - TD (OA) ²	Ireland - IE (EP) ²	Niger - NE (OA) ²	Trinidad and Tobago - TT
Chile - CL	Israel - IL	Nigeria - NG	Tunisia - TN
China - CN ✓	Italy - IT (EP) ²	Norway - NO (EP)	Turkey - TR (EP)
Colombia - CO			Turkmenistan - TM (EA)
Comoros - KM	Japan - JP	Oman - OM	
Congo - CG (OA) ²	Kazakhstan - KZ (EA)	Panama - PA ⁴	Uganda - UG (AP)
Costa Rica - CR	Kenya - KE (AP)	Papua New Guinea - PG	Ukraine - UA
Côte d'Ivoire - CI (OA)	North Korea - KP	Peru - PE	United Arab Emirates - AE ✓
Croatia - HR (EP)	South Korea - KR	Philippines - PH	United Kingdom - GB (EP)
Cuba - CU	Kyrgyzstan - KG (EA)	Poland - PL (EP)	United States of America - US ✓
Cyprus - CY (EP) ²		Portugal - PT (EP)	Uzbekistan - UZ
Czech Republic - CZ (EP)	Laos People's Dem. Rep. - LA	Qatar - QA	
Denmark - DK (EP)	Latvia - LV (EP) ²	Romania - RO (EP)	Vietnam - VN
Dominica - DM	Lesotho - LS (AP)	Russian Federation - RU (EA)	Zambia - ZM (AP)
Dominican Republic - DO		Rwanda - RW	Zimbabwe - ZW (AP)

Regional Patents

European Patent (EP)²: AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PO, PT, RO, RS, SE, SI, SK, SM, TR
(Extension possible for: AL, BA, ME)

Eurasian Patent (EA)⁵: AM, AZ, BY, KG, KZ, RU, TJ, TM

OAPI (African Intellectual Property Organisation) Patent (OA): BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

ARIPO (African Regional Industrial Property Organisation) Patent (AP): GH, GM, KE, LR, LS, MW, MZ, SD, SI, SZ, TZ, UG, ZM, ZW

¹ Extension of European Patent possible.

² May only be designated for a Regional Patent (the "national route" via the PCT has been closed).

³ EP does not include Andorra.

⁴ On 3 June 2006, the former state of Serbia & Montenegro (YU) divided into the Republic of Serbia (RS) and the Republic of Montenegro (ME).

⁵ Brunei Darussalam (BN) is available from 24 July 2012.

⁶ Panama (PA) is available from 7 September 2012.

⁷ EA no longer includes Moldova (MD) from 26 April 2012.

MewburnEllis LLP

Dr Bruce Roser
c/o Stablepharma Limited
1 Queen Square
Bath
BA1 2HA

European Patent Attorneys
European Trade Mark Attorneys
European Design Attorneys
Chartered Patent Attorneys

Norham House
Cambridge Business Park
Cambridge CB4 0WZ

Tel: +44 (0)1223 420363
Fax: +44 (0)1223 423792
mal@mewburn.com

Partners
Roger Calderbank
Patrick Stoner
Sean Walton
Nigel Hockney
Simon Kiddie
Adrian Braswell
Roger Grimshaw
Simon Kramer
Joanna Cripps
Robert Watson
Christopher Denton
Nicholas Setcliffe
Sofia Arenal
Matthew Naylor
Stephen Gutter

Stephen Gill
Wilhelm Wrytenburg
Graham Forrest
Richard Clogg
Rachel Okey

Rebecca Tollervey
Jeremy Webster
Richard Johnson
Henry van der Hoff
Lindsey Woolley
Simon Pardy
Kerry Moroney
Sam Bailey
Grace Moore
Stephen Hodsdon
Christopher Casley
Jonathan Willis
Julie Carlisle
Tania Keirstead
James Leach
Emily Hayes

Qualified Staff
Robert Andrews
Michael Foster
Katherine Green

Edmund Harrison
Susan Harrison
Sean Jauss
Nicola Kimlin
Andy King
Joseph Lanthall
June Lyons
Kathryn Nicholls
Frances Salisbury
Matthew Smith
Jocillan Stafford
Ian Stuart
Laurence Toime
Rachel White

Consulting Partners
Ian Armitage
Hugh Paget

www.mewburn.com

17 May 2013

By email only

Dear Bruce

International Patent Application No. PCT/GB2013/050183
Applicant: STABLEPHARMA LIMITED
Your Ref: Improved Injections PCT
Our Ref: KSG/CP6878896

We have now received the international search report on this PCT application. A copy is attached, along with copies of the cited documents.

The international search is intended to find documents that may be relevant to the patentability of the invention. The search report is accompanied by a written opinion on patentability, written by the searcher. The intention of this is to give you an early indication of the likely prospects for patentability of the invention.

Comments on search report and written opinion

Good news: the written opinion is positive. It states that the invention is patentable, i.e. the subject matter of all claims is novel, inventive and industrially applicable. The written opinion is, I think, quite self-explanatory - but if you would like to discuss it over the phone, or if you would like a more detailed analysis then please just say.

The search report cites four documents as category "A", meaning that the searcher considers them as providing background information only, rather than as being detrimental to patentability of the invention. Copies of these cited documents are attached.

The disclosure that the searcher considers as being closest to the claimed invention is that of patent application WO 2007/057717, which is one of your earlier patent applications that you had told us about.

The cited documents include another of your earlier applications, EP 1452171. The other two citations are patent applications filed by others (WO 2011/042542 and US 7,153,472).

Since we are already familiar with WO 2007/057717, and since the searcher does not consider any of the citations to destroy novelty or inventive step of your invention, we have not reviewed these documents in any detail. However, if you would like us to review them and provide comments then please just let me know.

Future procedure

The 30 month date for national/regional phase entry is **27 August 2014**. We intend to write to you again nearer the time to remind you about that date. If you are interested in initiating the national/regional phase examination of this application earlier than 27 August 2014, then please just let me know.

It is not compulsory at this stage to respond to the search report or written opinion. **And in the present case, since the searcher's written opinion is positive, it seems most appropriate to do nothing at this stage.**

However, there are in principle several optional steps we can take, so I will just run through them all for you. Our options at this stage are:

- A) File informal comments about the cited documents and the written opinion of the searcher. These can be filed at any time. There is no official fee. If the searcher has objections then this can be an inexpensive way to try to counter them. In your case the searcher has no objections, so there doesn't seem to be any reason for filing informal comments.
- B) File amendments to the claims now. This might be suitable if you want to restrict the scope of the claims immediately. These amended claims will be published. The time limit for filing amendments for publication is 16 July 2013. We will not remind you about this time limit again unless you ask us to. In the present case, there doesn't seem to be any reason why you would want to restrict the scope of the claims.
- C) File a Demand for international preliminary examination (IPE). The time limit for doing this is 27 November 2013. We will not remind you about this time limit again unless you ask us to. Filing a demand is only appropriate when the searcher has raised objections against the claims. In your case, therefore, there's no reason why we should file a demand.
- D) **Do nothing now.** If necessary, any issues raised in the search report and written opinion can be dealt with before the relevant national/regional offices of interest, once this application has entered the national/regional phase.

Since the searcher's opinion on patentability of your invention is positive, I advise taking option D, i.e. do nothing now.

As I said at the start of this letter, this positive opinion is good news. Since the searcher acting for the International Searching Authority works for the European Patent Office, this positive opinion means that it is likely that your application will go to grant relatively straightforwardly at least at the European Patent Office.

Our information sheets on the PCT procedure are attached.

MewburnEllis
LLP

3

Please call if you would like to discuss any of this.

Yours sincerely



Katherine Green
For Mewburn Ellis LLP
katherine.green@mewburn.com

Enc: International Search Report
Cited documents
Information sheets

cc: Nick Child

Document number: 11517686

Contact Details



Stablepharma Ltd, 4 Queen Street, Bath BA1 1HE
Telephone 01225 581 220 | email nchild@stablepharma.com

